Commercial Stage RNA Platform For Next Generation Cures in Cancer and Infectious Diseases
By analyzing RNA we can detect disease, monitor health, and design next-generation cures.

Only 1 out of 4 cancer treatments prolong life while we are spending $100 Billion on drugs and 8 million patients die every year because we treat them the same way. We aim to make cancer a chronic disease by disrupting the current standard of care with a dynamic truly individualized treatment model.

Our OneRNA® platform enables a paradigm shift from ONE disease, ONE marker, and ONE drug to ONE patient, MANY markers, and MULTIPLE treatment options that go beyond drugs. This is truly individualized medicine, by identifying a handful of actionable markers in all patient samples and a liquid biopsy platform for monitoring response and progression.

OneRNA® enables the design of mRNA vaccines as well as the design of sophisticated combinatorial clinical studies (one drug won’t cure cancer but 2 or 3 combo...
Commercial Stage RNA Platform For Next Generation Cures in Cancer and Infectious Diseases
By analyzing RNA we can detect disease, monitor health, and design next-generation cures.

Only 1 out of 4 cancer treatments prolong life while we are spending $100 Billion on drugs and 8 million patients die every year because we treat them the same way. We aim to make cancer a chronic disease by disrupting the current standard of care with a dynamic truly individualized treatment model.

Our OneRNA® platform enables a paradigm shift from ONE disease, ONE marker, and ONE drug to ONE patient, MANY markers, and MULTIPLE treatment options that go beyond drugs. This is truly individualized medicine, by identifying a handful of actionable markers in all patient samples and a liquid biopsy platform for monitoring response and progression.

OneRNA® enables the design of mRNA vaccines as well as the design of sophisticated combinatorial clinical studies (one drug won’t cure cancer but 2 or 3 combo’s could).

Genomic Expression was in the top 10 of the XTC, presented for Richard Branson at Necker Island, won the Lyfebulb and the EUTop50 award, and presented at the UN and the European Parliament, and more recently got into the finals of the XPRIZE for a novel COVID19 test using Next Generation Sequencing to massively scale access to testing and featured in Forbes.

OneRNA® is a disease agnostic exponentially scalable platform, CLIA validated in several clinical studies in women’s cancer first. OneRNA® is using proprietary sample prep to sequence FFPE tissue, blood, and saliva and proprietary algorithms and databases to generate a clinical report. The OneRNA® backend informatics platform is HIPAA, GPDR, and CLIA compliment and tracks everything from order to delivery of the clinical report. This enables us to deliver a saliva collection kit to the test subject and track everything all the way to the delivery of the result.
More information

Investors

Kim Tennican
Admin
Larry Siedlick
Admin
Larry Siedlick
Dan Adams
Admin
Dan Adams
Jim Orphanides
Admin
Jim Orphanides
Startupbootcamp Open Pitch Days New York
Admin
Startupbootcamp Open Pitch Days New York Taking place in Amazon offices on the 4th of February.

Advisors

Mette Skjold Rotboll
Admin
Mette Skjold Rotboll Advisory Board Member, Relationships Strong believer in “Doing well, while doing good”. Working globally with focus on the social and environmental side of investing for profit.
Steve Zelson
Admin
Steve Zelson
Kirsten Dinesen
Admin
Kirsten Dinesen
Ulrik Nielsen
Admin
Ulrik Nielsen

Employees

Jesper Zeuthen
Admin

Recommendations

Gitte Pedersen of Genomic Expression is an exceptional entrepreneur, a seasoned leader and someone I respect personally. She was the winner of the Lyfebulb Helsinn Innovation Award by Dr Squinto and Ms LePera in March 2018, where her personal inspiration for creating the company was judged in addition to the business and patient impact. I personally believe the vision and the early accomplishments by the company will be highly valuable to patients and even prevent people from, becoming patients!

I have had the pleasure of knowing Genomic Expression and watching it develop from a very early stage over the past 3 years. The company's CEO Gitte Pederson is uniquely qualified from both an academic and work experience standpoint. Her academic credentials are directly related to this field as is her work experience. Importantly she is extremely passionate and motivated to drive the creation of a replicable, scalable solution to health through her work in RNA analysis, diagnostics and genetically based cure to cancer.

Importantly, the success of this company in delivering a product and solution that enables 'a cure' -- will have tremendous impact on a very large number of people in terms of longer and more productive lives, and also potentially could save families billions of dollars in costs (depending on how wide spread the solution could be deployed) .

A solution like hers needs to, and will exist at some point in the future. I have no shares / no financial interest BTW.

From 1972 to 2009 I was the co founder and CEO of Sunrise Medical Laboratories, Inc. which is a CLIA and College of American Pathologists (CAP) certified medical laboratory which provided advanced biomedical services to physicians and hospitals.

I have invested in Genomic Expression because I believe it offers a promising and innovative approach to enhancing the treatment of cancer patients. In a short period of time I have watched the Genomic Expression team move this innovative technology from a prototype to revenue generating product.

Their patient centric testing protocol helps better guide physicians to an appropriate drug that has the best chance of extending patient lives as well as improving their quality of life.

In my over 35 years experience in the field of diagnostic medical laboratory I have overseen the implementation of numerous innovative patient technologies but none more exciting then the promise of Genomic Expression.

A truly disruptive way of thinking diagnostics - and a groundbreaking academic research - is the fundament of Genomic Expression. I chose to participate as a board member of two good reasons: to stop the inefficient way the health system today spend money/medication without knowing the effect - and this system that maintain the patient in long and costly treatment based on "let's try". Via the advanced RNA technology we can provide the right medication faster - and via a new business model, we can disrupt the way especially cancer treatment is conducted to day. Tomorrow it might be a range of other serious diseases.

I first met Gitte at a Lyfebulb-Helsinn Oncology Summit in Monte Carlo where she presented her work on RNA sequencing-based diagnostics for certain cancers. I served as a panelist and judge and the judges felt so strongly about her work and its potential that she was awarded a $25,000 prize. I find Gitte to be extremely intelligent, entrepreneurial and delightful. I believe her scientific approach has tremendous potential to change how we think about early cancer detection. I could not recommend Gitte and Genomic Expression any stronger based on the potrential of this clever technology.

I fully support Genomic Expression's efforts to achieve a more efficient approach towards analyzing gene expression in primary cancer cells. To date, while personalized medicine in oncology is becoming more widespread, it is currently limited to sequencing of the DNA of the patient’s cancer cell. This provides very important but still somewhat limited characterization of the tumor as it does not indicate if those genes exhibiting possible mutation are indeed being expressed at the RNA and protein level. Genomic Expressions is taking this analysis to the next level. Their OneRNA assay is the first actionable RNA sequencing assay in oncology. With this unique assay, 34,000 different RNA transcripts can be identified and quantified. This will revolutionize cancer therapy as it will allow clinicians to directly target specific gene expression and not only block the tumor cell replication but directly trigger tumor cell death.

Howard A Young, Ph.D.

Genomic Expression is the beneficiary of EIC pilot SME Instrument Ph2 grant, the funding programme within Horizon 2020. This programme funds innovative projects with the potential to disrupt existing markets.